Navigation Links
Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
Date:1/8/2009

SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 10:00 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 2016 , ... Of the variety of ingredients in the food supply, few ... to common beliefs that hot dogs include “everything but the oink,” today’s wieners are ... combined with meat and poultry in a hot dog recipe can add flavor, keep ...
(Date:12/6/2016)... ... 06, 2016 , ... The NALA, a boutique marketing agency, is proud to ... (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families of children ... TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in four boxes ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center of ... the organization as a top behavioral service provider in the country. The award ... staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via a ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... Switzerland (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, ... certificates, and more. , To access more than 9,000 documents, webinars and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Mallinckrodt Pharmaceuticals ... pharmaceutical company, today announced that it received a perfect ... Index (CEI), a national benchmarking survey and report on ... and transgender (LGBT) workplace equality, administered by the Human ... 517 major U.S. businesses which also earned top marks ...
(Date:12/5/2016)... 5, 2016  Cornerstone Pharmaceuticals, Inc., a privately ... from two Phase I trials evaluating its lead ... annual meeting of the American Society of Hematology ... . The two datasets show encouraging efficacy and ... (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, ...
(Date:12/5/2016)... BOULDER, Colo. , Nov. 29, 2016 ... webinar hosted by Accera, Inc. at 11 ... 9th Annual International Conference on Clinical Trials for Alzheimer,s ... role of metabolism in Alzheimer,s disease and therapeutic targets ... patients. "Following the recent failure of another ...
Breaking Medicine Technology: